Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04134923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04134923 · ClinicalTrials.gov record · last posted 2025-08-07

Imaging Biomarkers in Preclinical and Symptomatic AD

Study acronym: ACS_PIB_IND
StatusRecruiting
PhaseNot specified
Started2021-06-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2019-10-21; most recent amendment 2025-08-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-06-29
Status change Active, Not Recruiting→Recruitingv2
2020-05-28
Status change Enrolling by Invitation→Active, Not Recruitingv1
Trial Details
NCT Number NCT04134923
Lead Sponsor Tammie L. S. Benzinger, MD, PhD
Conditions Alzheimer Disease
Enrollment 375 participants
Start Date 2021-06-08
Primary Completion 2026-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-08-07